345 related articles for article (PubMed ID: 32942205)
1. The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review.
Zhang S; Zhu Q; Chen JY; OuYang D; Lu JH
Phytomedicine; 2020 Dec; 79():153316. PubMed ID: 32942205
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review.
Khalifa MKA; Abdel-Sattar SA; Amin OM; Kohaf NA; Zaky HS; Abd El-Fattah MA; Mohammed KHA; Badawi NM; Mansoor I; Eassa HA
Daru; 2024 Jun; 32(1):319-337. PubMed ID: 38079104
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats.
Nan S; Wang P; Zhang Y; Fan J
Drug Des Devel Ther; 2021; 15():2013-2024. PubMed ID: 34012254
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease.
Guo Y; Zhao Y; Nan Y; Wang X; Chen Y; Wang S
Neuroreport; 2017 Jul; 28(10):590-597. PubMed ID: 28520620
[TBL] [Abstract][Full Text] [Related]
5. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Smith A; Giunta B; Bickford PC; Fountain M; Tan J; Shytle RD
Int J Pharm; 2010 Apr; 389(1-2):207-12. PubMed ID: 20083179
[TBL] [Abstract][Full Text] [Related]
6. Increased BBB permeability contributes to EGCG-caused cognitive function improvement in natural aging rats: pharmacokinetic and distribution analyses.
Wei BB; Liu MY; Zhong X; Yao WF; Wei MJ
Acta Pharmacol Sin; 2019 Nov; 40(11):1490-1500. PubMed ID: 31092885
[TBL] [Abstract][Full Text] [Related]
7. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice.
Lee JW; Lee YK; Ban JO; Ha TY; Yun YP; Han SB; Oh KW; Hong JT
J Nutr; 2009 Oct; 139(10):1987-93. PubMed ID: 19656855
[TBL] [Abstract][Full Text] [Related]
8. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease.
Xicota L; Rodriguez-Morato J; Dierssen M; de la Torre R
Curr Drug Targets; 2017; 18(2):174-195. PubMed ID: 26302801
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.
Mori T; Koyama N; Tan J; Segawa T; Maeda M; Town T
J Biol Chem; 2019 Feb; 294(8):2714-2731. PubMed ID: 30563837
[TBL] [Abstract][Full Text] [Related]
10. [Research on EGCG improving the degenerative changes of the brain in AD model mice induced with chemical drugs].
He M; Liu MY; Wang S; Tang QS; Yao WF; Zhao HS; Wei MJ
Zhong Yao Cai; 2012 Oct; 35(10):1641-4. PubMed ID: 23627134
[TBL] [Abstract][Full Text] [Related]
11. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model.
Cano A; Ettcheto M; Chang JH; Barroso E; Espina M; Kühne BA; Barenys M; Auladell C; Folch J; Souto EB; Camins A; Turowski P; García ML
J Control Release; 2019 May; 301():62-75. PubMed ID: 30876953
[TBL] [Abstract][Full Text] [Related]
12. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
Rezai-Zadeh K; Arendash GW; Hou H; Fernandez F; Jensen M; Runfeldt M; Shytle RD; Tan J
Brain Res; 2008 Jun; 1214():177-87. PubMed ID: 18457818
[TBL] [Abstract][Full Text] [Related]
13. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
14. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).
Singh NA; Mandal AK; Khan ZA
Nutr J; 2016 Jun; 15(1):60. PubMed ID: 27268025
[TBL] [Abstract][Full Text] [Related]
15. Natural antioxidants enhance the power of physical and mental activities versus risk factors inducing progression of Alzheimer's disease in rats.
Ali AA; Abd El-Fattah AI; Abu-Elfotuh K; Elariny HA
Int Immunopharmacol; 2021 Jul; 96():107729. PubMed ID: 33971493
[TBL] [Abstract][Full Text] [Related]
16. Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia.
Biasibetti R; Tramontina AC; Costa AP; Dutra MF; Quincozes-Santos A; Nardin P; Bernardi CL; Wartchow KM; Lunardi PS; Gonçalves CA
Behav Brain Res; 2013 Jan; 236(1):186-193. PubMed ID: 22964138
[TBL] [Abstract][Full Text] [Related]
17. Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice.
Giunta B; Hou H; Zhu Y; Salemi J; Ruscin A; Shytle RD; Tan J
Neurosci Lett; 2010 Mar; 471(3):134-8. PubMed ID: 20096749
[TBL] [Abstract][Full Text] [Related]
18. EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.
Fernandez JW; Rezai-Zadeh K; Obregon D; Tan J
FEBS Lett; 2010 Oct; 584(19):4259-67. PubMed ID: 20849853
[TBL] [Abstract][Full Text] [Related]
19. (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
Chang X; Rong C; Chen Y; Yang C; Hu Q; Mo Y; Zhang C; Gu X; Zhang L; He W; Cheng S; Hou X; Su R; Liu S; Dun W; Wang Q; Fang S
Exp Cell Res; 2015 May; 334(1):136-45. PubMed ID: 25882496
[TBL] [Abstract][Full Text] [Related]
20. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
Okello EJ; Mather J
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
